Circulating Tumour DNA as a Potential Cost-Effective Biomarker to Reduce Adjuvant Chemotherapy Overtreatment in Stage II Colorectal Cancer
Cell-free DNA as a biomarker in cancer
MRD Detection Emerges as a Catalyst for Advances in Colon Cancer
Cancers, Free Full-Text
The Application of Circulating Tumor DNA in the Screening
Adnan Khattak on LinkedIn: 'A ctDNA-guided approach to the treatment of stage II colon cancer reduced…
Cancer Research and Treatment
Lessons learned in adjuvant colorectal cancer
ASCO 2022 update: (neo-)adjuvant treatment of colorectal cancer
Dissected subgroups predict the risk of recurrence of stage II
Circulating Tumor DNA: Towards More Individualized Treatment for
Oncology Data Advisor - Guiding Colorectal Cancer Treatment Decisions Using ctDNA
